Galecto Announces Key Additions to Leadership Team
Galecto appointed Sherwin Sattarzadeh, former Chief Business Officer of Blueprint Medicines, as Chief Operating Officer effective January 5, 2026.
Galecto appointed Dr. Becker Hewes, former Chief Medical Officer of Blueprint Medicines, as Chief Medical Officer effective January 5, 2026.
The appointments were announced on January 6, 2026.
Inducement grants:
Sattarzadeh received 190,376 RSUs and options for 444,209 shares; Hewes received 264,629 RSUs and options for 528,603 shares.
DMR-001, a mutCALR-targeting monoclonal antibody, is on track for IND submission in mid-2026 with first-in-human subcutaneous dosing.
Galecto's cash runway extends into 2029 following a $285 million PIPE in November 2025.